Intelence Drug Interactions

Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of INTELENCE with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of INTELENCE (see Table 11). [See also Pharmacology: Pharmacokinetics: Special Populations: Drug Interactions under Actions.]
Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-glycoprotein with INTELENCE may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s) (see Table 11). [See also Pharmacology: Pharmacokinetics: Special Populations: Drug Interactions under Actions.]
Table 11 shows the established and other potentially significant drug interactions based on which, alterations in dose or regimen of INTELENCE and/or co-administered drug may be recommended. Drugs that are not recommended for co-administration with INTELENCE are also included in Table 11. (See Tables 11a and 11b.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

In addition to the drugs included in Table 11, the interaction between INTELENCE and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see Pharmacology: Pharmacokinetics: Special Populations: Drug Interactions under Actions]: didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate.